Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with mistletoe preparation (Iscador): A re-analysis

European Journal of Medical Research

Volumn 11, Issue 11, 2006, Pages 485-495

  Grossarth Maticek, R ^a   Ziegler, Renatus ^b  

^a Institute for Preventive Medicine   (Germany)

^b Institut Hiscia   (Switzerland)

Author keywords

Breast cancer; Complementary anthroposophic therapies; Mistletoe preparation (Iscador); Overall survival; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE DERIVATIVE; VISCUM ALBUM LECTIN;

ALTERNATIVE MEDICINE; ANALYTIC METHOD; ARTICLE; AUTOREGULATION; BREAST CANCER; BREAST SURGERY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; COPING BEHAVIOR; DATA ANALYSIS; DRUG EFFECT; HUMAN; LONG TERM CARE; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; OVERALL SURVIVAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PSYCHOSOMATICS; SENSITIVITY ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM RECURRENCE, LOCAL; PHYTOTHERAPY; PLANT EXTRACTS; PLANT PROTEINS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 33845518673     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Altman DG, Whitehead J, Parmar MK, Stenning SP, Fayers PM, Machin DM (1995) Randomised consent design in cancer clinical trials. Eur J Cancer 31A (12): 1934-1944
2. Grossarth-Maticek R (1999) Systemische Epidemiologie und präventive Verhaltensmedizin chronischer Erkrankungen. Strategien zur Aufrechterhaltung der Gesundheit. Berlin: Walter de Gruyter
3. Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R (2001) Use of Iscador, an extract of european mistletoe (viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pairs studies nested within a cohort study. Altern Ther Health Med 7 (3): 57-78
4. Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R (2001) Addendum to Iscador article. Altern Ther Health Med 7 (4): 26
5. Grossarth-Maticek R, Ziegler R (2005) Randomisierte Kohortenstudien im Matched-Pair-Design zur Misteltherapie (Iscador) bei gynäkologischen Karzinomen. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H (eds) Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag, 611-623
6. Hosmer DW, Lemeshow S (1999) Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: Wiley
7. Hougaard P (2000) Analysis of Multivariate Survival Data. New York: Springer
8. Lehmann EL (1975) Non-parametrics: Statistical Methods Based on Ranks. San Francisco: Holden-Day
9. Mehta C, Patel N (eds) (2003) StatXact 6: Statistical Software for Exact Nonparametric Inference, User Manual. Cambridge MA: Cytel Software Corporation
10. Moher D, Schulz KF, Altman DG (2001) The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Med Assoc 285: 1987-1991
11. Reeves BC (2004) Reasons for caution when evaluating health care interventions using non-randomised study designs. Forsch Komplementärmed Klass Naturheilkd 11 (suppl 1): 40-45
12. Reeves BC, Gaus W (2004) Guidelines for reporting non-randomised studies. Forsch Komplementärmed Klass Naturheilkd 11 (suppl 1): 46-52
13. Tableman M, Kim JS, Portnoy S (2004) Survival Analysis Using S: Analysis of Time-to-Event Data. Boca Raton: Chapman & Hall / CRC
14. Zelen M (1979) A new design for randomized clinical trials. N Engl J Med 300 (22): 1242-1245
15. Zelen M (1990) Randomized consent designs for clinical trials: an update. Stat Med 9: 645-656